ADCs

With over ten years of experience supporting antibody drug conjugate (ADC) discovery, development and manufacturing, our multidisciplinary team has worked with a range of different antibodies, linkers and toxins to enable us to develop customised bioconjugation approaches and offer complex ADC solutions to our customers.

ADC manufacturing facilities at Sterling Pharma Solutions' Deeside, Wales facilities

Blog7 min read

Top 5 considerations in ADC clinical manufacturing Read more

Popular in this category

Molly Monahan - Production Supervisor

Spotlight4 min read

Sterling Snapshot | Molly Monahan, Production Supervisor Read more

Blog6 min read

Top 5 considerations in ADC process development Read more

Spotlight5 min read

Scientist Snapshot | Stephanie Johnson, Principal Process Development Scientist Read more

One pager3 min read

Linker payloads Read more

All articles

Measurement of ADC stability in serum via subunit DAR analysis

One pager3 min read

Measurement of ADC stability in serum via subunit DAR analysis

Stability of biologics is a critical quality attribute (CQA) affecting the levels of dosing and efficacy.

Read more

Peptide digestion analysis of an antibody drug conjugate

One pager3 min read

Peptide digestion analysis of an antibody drug conjugate Read more

Sterling's Deeside, UK facility

Article6 min read

Partnering for ADCs: What to look for in a contract development and manufacturing organisation (CDMO) Read more

Blog5 min read

Overcoming purification hurdles for ADC linker payloads Read more

Mass spectrometry

One pager3 min read

Stability of ADCs in sub-cellular fractions Read more

ADC manufacturing facilities at Sterling Pharma Solutions' Deeside, Wales facilities

News2 min read

Kivu Bioscience Selects Sterling for cGMP Manufacturing of Lead Oncology ADC Read more

Stability of ADC linker payloads in sub-cellular fractions

One pager3 min read

Stability of ADC linker payloads in sub-cellular fractions Read more

ADCs at Sterling

News2 min read

GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production Read more

News2 min read

Sterling Expands GMP ADC Manufacturing Capacity at Deeside, UK Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

LinkedIn

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229